Zobrazeno 1 - 10
of 34
pro vyhledávání: '"John R. Toomey"'
Autor:
Ian Moench, Christine G. Schnackenberg, Gatto Gregory J, John R. Toomey, Joanne Kuziw, Karpagam Aravindhan, Robert N. Willette
Publikováno v:
Journal of the Endocrine Society
Increased fibroblast growth factor 23 (FGF23) levels are an independent predictor for adverse cardiac events suggesting a role as a link that drives cardiomyopathic changes in cardiorenal syndrome. The search for the underlying mechanism driving this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e80b39b405185ac883aca2431326e30
https://doi.org/10.1210/jendso/bvab066
https://doi.org/10.1210/jendso/bvab066
Autor:
John R. Toomey, John J. Upson
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 9:e199-e203
With a few notable exceptions, heart failure (HF) drug development has faced substantial attrition while translating preclinical discoveries into clinical efficacy. The high attrition has prompted a reconsideration of the target selection process of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2fb6677973f3f4162194546cca129f7
https://doi.org/10.1016/j.ddstr.2014.01.003
https://doi.org/10.1016/j.ddstr.2014.01.003
Autor:
Stefan Senger, Máire A. Convery, Robert J. Young, Stephanie Irvine, Iain M. McLay, Robert I. West, David J. Belton, Savvas Kleanthous, Carl Adams, John R. Toomey, Anne M. Exall, Anthony J. Pateman, Theresa J. Roethke, Caroline M. Whittaker, Laiq Chaudry, David E. Davies, Angela Patikis, Cynthia L. Burns-Kurtis, Nigel S. Watson, Gary J. Stelman, David W. Brown, John D. Harling, Wendy R. Irving, Chuen Chan, Ping Zhou
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:1588-1592
The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff85f937ce4e89e1a2bcffaac9ddca4
https://doi.org/10.1016/j.bmcl.2011.01.129
https://doi.org/10.1016/j.bmcl.2011.01.129
Autor:
Savvas Kleanthous, Alan D. Borthwick, David Brown, Cynthia L. Burns-Kurtis, Matthew Campbell, Laiq Chaudry, Chuen Chan, Marie-Olive Clarte, Máire A. Convery, John D. Harling, Eric Hortense, Wendy R. Irving, Stephanie Irvine, Anthony J. Pateman, Angela N. Patikis, Ivan L. Pinto, Derek R. Pollard, Theresa J. Roethka, Stefan Senger, Gita P. Shah, Gary J. Stelman, John R. Toomey, Nigel S. Watson, Robert I. West, Caroline Whittaker, Ping Zhou, Robert J. Young
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:618-622
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa inhibitors, incorporating neutral and basic monoaryl P4 groups, ultimately producing potent inhibitors with effective levels of ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c703cdb093d395dc4c312cc73a2b70
https://doi.org/10.1016/j.bmcl.2009.11.077
https://doi.org/10.1016/j.bmcl.2009.11.077
Autor:
Connie L. Erickson-Miller, Joseph A. Erhardt, Kodandaram Pillarisetti, Manuel Aivado, Melanie A Abboud, John R. Toomey
Publikováno v:
Experimental Hematology. 37:1030-1037
Objective The thrombopoietin receptor (TPOR) is a therapeutic target for treatment of thrombocytopenia because stimulation of this receptor results in enhanced megakaryocyte proliferation, differentiation, and ultimately platelet production. In addit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f57bf92d9cae185d4bf7d8eccaee08a
https://doi.org/10.1016/j.exphem.2009.06.011
https://doi.org/10.1016/j.exphem.2009.06.011
Autor:
Anthony J. Pateman, John R. Toomey, Paul F. Koster, Augustin Amour, Saul Needle, Laiq Chaudry, Melanie A Abboud, Champa Patel, Angela Patikis, Cynthia L. Burns-Kurtis, Robert J. Young, Richard E. Valocik, David Brown, Ping Zhou, Chuen Chan, Nigel S. Watson
Publikováno v:
Journal of Cardiovascular Pharmacology. 52:66-71
Background: Factor Xa (FXa) has been a target of considerable interest for drug development efforts aimed at suppressing thrombosis. In this report, a new orally active, small molecule, active-site directed FXa inhibitor, GW813893, has been profiled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4ecf88e87e341213f5fef72bbcb248
https://doi.org/10.1097/fjc.0b013e31817e9b9e
https://doi.org/10.1097/fjc.0b013e31817e9b9e
Autor:
Alan D. Borthwick, Marie Charbaut, Robert J. Young, Máire A. Convery, Ivan Leo Pinto, Andrew M. Mason, Weston Helen Elisabeth, Matthew Campbell, David W. Brown, Anthony J. Pateman, Henry Anderson Kelly, Derek Pollard, Shah Gita Punjabhai, John R. Toomey, N. Paul King, Stefan Senger, Eric Hortense, Ping Zhou, Hawa Diallo, Nigel S. Watson, Wendy R. Irving, Angela Patikis, Cynthia L. Burns-Kurtis, Savvas Kleanthous, Chuen Chan
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:28-33
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating basic biaryl P4 groups, producing highly potent inhibitors with significant anticoagulant activitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03145f782eb525e093f927857c7919cd
https://doi.org/10.1016/j.bmcl.2007.11.019
https://doi.org/10.1016/j.bmcl.2007.11.019
Autor:
Robert J. Young, David W. Brown, Stefan Senger, Chuen Chan, Máire A. Convery, Anthony J. Pateman, Nigel S. Watson, John R. Toomey, Ping Zhou, Henry Anderson Kelly, Shah Gita Punjabhai, Julia A. Hubbard, Angela Patikis, Cynthia L. Burns-Kurtis
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:2927-2930
The synthetic entry to new classes of dual fXa/thrombin and selective thrombin inhibitors with significant oral bioavailability is described. This was achieved through minor modifications to the sulfonamide group in our potent and selective fXa inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29c69eec9dfca70c859103d7b56e8c3a
https://doi.org/10.1016/j.bmcl.2007.03.080
https://doi.org/10.1016/j.bmcl.2007.03.080
Autor:
Christine G. Schnackenberg, Weike Bao, Robert N. Willette, Anna Zacco, Thimmaiah P Chendrimada, John R. Toomey
Publikováno v:
The FASEB Journal. 29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2f63f64cca01f0b3dc35a3db52b1399
https://doi.org/10.1096/fasebj.29.1_supplement.955.6
https://doi.org/10.1096/fasebj.29.1_supplement.955.6
Autor:
Uri Seligsohn, David Gailani, S Bulvik, John R. Toomey, Taketoshi Ogawa, Jacqueline M. Lane, Ariella Zivelin, Meytal Landau
Publikováno v:
Journal of Thrombosis and Haemostasis. 2:1782-1789
During normal hemostasis, the coagulation protease factor (F)XIa activates FIX. Hereditary deficiency of the FXIa precursor, FXI, is usually associated with reduced FXI protein in plasma, and circulating dysfunctional FXI variants are rare. We identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5b99e3cd2976c1d13736420797f42f
https://doi.org/10.1111/j.1538-7836.2004.00882.x
https://doi.org/10.1111/j.1538-7836.2004.00882.x